key: cord-1006026-5mr7ynx3
authors: Dong, Jinhui; Zost, Seth J.; Greaney, Allison J.; Starr, Tyler N.; Dingens, Adam S.; Chen, Elaine C.; Chen, Rita E.; Case, James Brett; Sutton, Rachel E.; Gilchuk, Pavlo; Rodriguez, Jessica; Armstrong, Erica; Gainza, Christopher; Nargi, Rachel S.; Binshtein, Elad; Xie, Xuping; Zhan, Xianwen; Shi, Pei-Yong; Logue, James; Weston, Stuart; McGrath, Marisa E.; Frieman, Matthew B.; Brady, Tyler; Tuffy, Kevin; Bright, Helen; Loo, Yueh-Ming; McTamney, Patrick; Esser, Mark; Carnahan, Robert H.; Diamond, Michael S.; Bloom, Jesse D.; Crowe, James E.
title: Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
date: 2021-01-28
journal: bioRxiv
DOI: 10.1101/2021.01.27.428529
sha: 18f6c98f251e363e6f366d60a88b1cfa44925aec
doc_id: 1006026
cord_uid: 5mr7ynx3

The SARS-CoV-2 pandemic has led to an urgent need to understand the molecular basis for immune recognition of SARS-CoV-2 spike (S) glycoprotein antigenic sites. To define the genetic and structural basis for SARS-CoV-2 neutralization, we determined the structures of two human monoclonal antibodies COV2-2196 and COV2-21301, which form the basis of the investigational antibody cocktail AZD7442, in complex with the receptor binding domain (RBD) of SARS-CoV-2. COV2-2196 forms an “aromatic cage” at the heavy/light chain interface using germline-encoded residues in complementarity determining regions (CDRs) 2 and 3 of the heavy chain and CDRs 1 and 3 of the light chain. These structural features explain why highly similar antibodies (public clonotypes) have been isolated from multiple individuals1–4. The structure of COV2-2130 reveals that an unusually long LCDR1 and HCDR3 make interactions with the opposite face of the RBD from that of COV2-2196. Using deep mutational scanning and neutralization escape selection experiments, we comprehensively mapped the critical residues of both antibodies and identified positions of concern for possible viral escape. Nonetheless, both COV2-2196 and COV2130 showed strong neutralizing activity against SARS-CoV-2 strain with recent variations of concern including E484K, N501Y, and D614G substitutions. These studies reveal germline-encoded antibody features enabling recognition of the RBD and demonstrate the activity of a cocktail like AZD7442 in preventing escape from emerging variant viruses.

although both the heavy and light chains are required to form this public clonotype (thus defining between the antibodies and ACE2 for RBD binding from our previous study, e.g., both COV2-148 of the heavy chain) that interact extensively with the epitope, they are encoded by germline 171 285 Nevertheless, not all antibody binding site residues were identified as sites where mutations 286 greatly reduced binding. Several explanations are possible: 1) some binding site residues may not 287 be critical for binding, 2) some RBD residues do not use their side chains to form interactions 288 with the mAbs or 3) mutations at some sites may not be tolerated for RBD expression 28 . For 289 instance, residues L455, F456, and Q493 are part of the structurally-defined binding site for 290 COV2-2196 (Fig. 1d) , but mutations to these sites did not impact antibody binding detectably 291 ( Fig. 4a and c) , suggesting that these residues do not make critical binding contributions. 292

Superimposition of the COV2-2196/RBD structure onto the S2E12/RBD structure clearly 293 demonstrates a flexible hinge region between the RBD ridge and the rest of the RBD that is 294 maintained when antibody is bound (Extended Data Fig. 2d ). This finding indicates that 295 mutations at these three positions could be well-tolerated for antibody-RBD binding and supports 296 the non-essential nature of these particular residues for COV2-2196 or S2E12 binding. 297 298 Importantly, COV2-2196 and COV2-2130 do not compete with one another for binding to the 299 RBD 1 , suggesting they could comprise an escape-resistant cocktail for prophylactic or 300 therapeutic use. Indeed, the binding sites and escape variant maps for these two antibodies are 301 non-overlapping. To test whether there were single mutations that could escape binding of both 302 antibodies, we performed escape variant mapping experiments with a 1:1 mixture of the COV2-303 2196 and COV2-2130 antibodies, but we did not detect any mutation that had an escape fraction 304 of greater than 0.2, whereas the mutations with the largest effects for each of the single 305 antibodies was approximately 1 (Extended Data Fig. 7d) . 306

Although these experiments map all mutations that escape antibody binding to the RBD, we also 308 sought to determine which mutations have the potential to arise during viral growth. To address 309 this question, we first attempted to select escape mutations using a recombinant VSV expressing 310 the SARS-CoV-2 S glycoprotein (VSV-SARS-CoV-2) 29 ; (Fig 4e) . We expected that the only 311 amino acid mutations that would be selected during viral growth were those 1) arising by single-312 nucleotide RNA changes, 2) causing minimal deleterious effect on ACE2 binding and 313 expression, and 3) substantially impacting antibody binding 27,28 . Indeed, we did not detect any 314 COV2-2196-induced mutations that were both single-nucleotide accessible and relatively well-315 tolerated with respect to effects on ACE2 binding (Fig. 4b) , which may explain why escape 316 mutants were not selected in any of the 88 independent replicates of recombinant VSV growth in 317 the presence of antibody ( Fig. 4e Extended Data Fig. 7g) . For COV2-2130, mutations to site 318 K444, a site that is relatively tolerant to mutation 28 , demonstrated the most frequent escape from 319 antibody binding in neutralization assays with the the VSV chimeric virus. K444R (selected in 6 320 out of 20 replicates) or K444E (selected in 2 out of 20 replicates) were identified in 40% of the 321 replicates of recombinant VSV growth in the presence of COV2-2130 (Fig. 4e Fig. 8) . As a control, virus was passaged in the 329 absence of antibody. Following the final passage, viruses were evaluated for susceptibility against the partner antibody at a final concentration of 10 times the IC 90 concentration by plaque 331 assay. We did not detect any plaques resistant to neutralization by AZD8895 (based on COV2-332 2196) or the AZD7442 cocktail. Virus that was passaged serially in AZD1061 formed plaques to 333 a titer of 1.2 × 10 7 PFU/mL after selection in 10 × the IC 90 value concentration of AZD1061, but 334 plaques were not formed with AZD7442. Plaques (n=6) were selected randomly, and the S gene 335 was amplified and sequenced, revealing the same 3 amino acid changes in all 6 of the 336 independently selected and sequenced plaques: N74K, R346I and S686G (Fig. 4f) . The S686G 337 change has been reported previously to be associated with serial passaging of SARS-CoV-2 in 338

Vero cells 30 , isolated from challenge studies in ferrets 31 or NHPs 32 , and is predicted to decrease 339 furin activity 30 . The N74K residue is located in the N-terminal domain outside of the AZD1061 340 binding site and results in the loss of a glycan 33 . The R346I residue is located in the binding site 341 of AZD1061 and may be associated with AZD1061-resistance. The impact of the R346I changes 342 on AZD1061 (COV2-2130) binding to S protein is shown in Fig. 4g . The K444R and K444E 343 substitutions selected in the VSV-SARS-CoV-2 system and the R346I substitution selected by 344 passage with authentic SARS-CoV-2 are accessible by single nucleotide substitution and 345 preserve ACE2 binding activity (Fig. 4g) , indicating that our DMS analysis predicted the 346 mutations selected in the presence of COV2-2130 antibody. Taken together, these results 347 comprehensively map the effects of all amino acid substitutions on the binding of COV2-2196 348 and COV2-2130 and identify sites of possible concern for viral evolution. That said, variants 349 containing mutations at residues K444 and R346 are rare among all sequenced viruses present in 350 the GISAID databases (all ≤ 0.01% when accessed on 12/23/20). 351

Recently, viral variants with increased transmissibility and potential antigenic mutations have 353 been reported in clinical isolates 34-37 . We tested whether some of the variant residues in these 354 rapidly emerging strains would abrogate the activity of these potently neutralizing antibodies. conformation as the reference. The color scheme of COV2-2196-RBD complex is the 502 same as that in Fig. 1a . The three subunits of spike are colored in grey, yellow, or light 503 blue respectively (the subunit with its RBD in "up" conformation is yellow). 504 d. Surface representation of RBD epitope recognized by COV2-2196. The epitope residues 505 are colored in different shades of green and labeled in black with the critical contact 506 residue F486 labled in white. 507 e. Antibody-antigen interactions between COV2-2196 and RBD. RBD is shown in the same 508 surface representation and orientation as that in Fig. 1d . COV2-2196 paratope residues 509 are shown in stick representation. The heavy chain is colored in cyan, and light chain is 510 colored in magenta. 

recombinant Fab was purified from culture supernatant using an anti-CH1 CaptureSelect column serum in DPBS containing 0.05% Tween-20 (DPBS-T) for 1 h. Antibodies were diluted to 10 778 µg/mL and titrated two-fold 23 times in DPBS-T and added to the wells, followed by an 779 incubation for 1 h at room temperature. The bound antibodies were detected using goat anti-780 human IgG conjugated with horseradish peroxidase (Southern Biotech) and TMB substrate 781 (Thermo Fischer Scientific). Reactions were quenched with 1 N hydrochloric acid and 782 absorbance was measured at 450 nm using a spectrophotometer (Biotek). 783

Mapping of all mutations that escape antibody binding 785 786

All mutations that escape antibody binding were mapped via a DMS approach 27 . We the total fraction of the library that escaped antibody binding via a previously described 823 formula 27 . These escape fractions represent the estimated fraction of cells expressing that 824 specific variant that fall in the antibody escape bin, such that a value of 0 means the variant is always bound by serum and a value of 1 means that it always escapes antibody binding. We then 826 applied a computational filter to remove variants with low sequencing counts or highly 827 deleterious mutations that might cause antibody escape simply by leading to poor expression of 828 properly folded RBD on the yeast cell surface 27,28 . Specifically, we removed variants that had (or 829 contained mutations with) ACE2 binding scores < −2.35 or expression scores < −1, using the 830 variant-and mutation-level deep mutational scanning scores as previously described 28 . Note that 831 these filtering criteria are slightly more stringent than those previously used to map a panel of 832 human antibodies 27 but are identical to those used in recent studies defining RBD residues that 833 impact the binding of mAbs 65 and polyclonal serum 40 . 834 835 We next deconvolved variant-level escape scores into escape fraction estimates for single 836 mutations using global epistasis models 66 implemented in the dms_variants package, as detailed 837 at (https://jbloomlab.github.io/dms_variants/dms_variants.globalepistasis.html) and described 27 . 838

The reported escape fractions throughout the paper are the average across the libraries 839 (correlations shown in Extended Data Fig. 7a,b) ; these scores are also in Supplementary Data 840 Table 1 . Sites of strong escape from each antibody for highlighting in logo plots were 841 determined heuristically as sites whose summed mutational escape scores were at least 10 times 842 the median sitewise sum of selection, and within 10-fold of the sitewise sum of the most strongly 843 We searched for antibody variable gene sequences originating with the same features as those 916 encoding COV2-2196 and retrieved the matching sequences from the repertoires of each individual examined. We searched for similar sequences in the publicly available large-scale 918 antibody sequence repertoires for three healthy individuals and cord blood repertoires (deposited 919 at SRP174305). The search parameters for the heavy chain were sequences with IGHV1-58 and 920 IGHJ3 with the P99, D108, and F110 residues. Additionally, the search parameters for the light 921 chain were sequences with Y92 and W98 residues. Sequences from a matching clonotype that 922 belonged to each individual were aligned with either ClustalO 69 (heavy chains) or with 923 MUSCLE 70 (light chains). Then, LOGOs plots of aligned sequences were generated using 924 

Potently neutralizing and protective human antibodies against SARS-927

Convergent antibody responses to SARS-CoV-2 in convalescent 929 individuals

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-931

Neutralizing Antibodies from COVID-19 Patients

Isolation of potent SARS-CoV-2 neutralizing antibodies and 972 protection from disease in a small animal model

A human neutralizing antibody targets the receptor-binding site of SARS-975

Infant and adult human B cell responses to rotavirus share 977 common immunodominant variable gene repertoires

Rapid isolation and profiling of a diverse panel of human monoclonal 987 antibodies targeting the SARS-CoV-2 spike protein

Deep mutational scanning of SARS-CoV-2 receptor binding domain 995 reveals constraints on folding and ACE2 binding

Neutralizing antibody and soluble ACE2 inhibition of a replication-998 competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2

SARS-CoV-2 growth, furin-cleavage-site adaptation and 1001 neutralization using serum from acutely infected hospitalized COVID-19 patients

The impact of mutations in SARS-CoV-2 spike on viral infectivity and 1009 antigenicity

Emergence and rapid spread of a new severe acute respiratory 1018 syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in 1019

Genomic characterization of a novel SARS-CoV-2 lineage from Rio 1022 de Janeiro, Brazil. medRxiv

Landscape analysis of escape variants identifies SARS-CoV-2 spike

Escape of SARS-CoV-2 501Y.V2 variants from neutralization by 1039 convalescent plasma. medRxiv

Immunodominance of the VH1-46 antibody gene segment in the primary 1042 repertoire of human rotavirus-specific B cells is reduced in the memory compartment 1043 through somatic mutation of nondominant clones

Focused evolution of HIV-1 neutralizing antibodies revealed by structures 1046 and deep sequencing

Structural and functional bases for broad-spectrum neutralization of avian 1061 and human influenza A viruses

H5N1 Vaccine-Elicited Memory B Cells Are Genetically 1064

Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the 1065

Broadly neutralizing antibodies with few somatic mutations and 1067

Overview of the CCP4 suite and current developments

Phaser crystallographic software

PHENIX: a comprehensive Python-based system for macromolecular 1089 structure solution

Inferring the shape of global 1097

An infectious cDNA clone of SARS-CoV-2

MUSCLE: a multiple sequence alignment method with reduced time and 1106 space complexity

WebLogo: a sequence logo 1108 generator

Receptor binding domain (RBD)

VSV-SARS-CoV-2 escape variant selection